A share price of Abbott Laboratories [ABT] is currently trading at $128.47, up 2.40%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ABT shares have gain 5.23% over the last week, with a monthly amount drifted -0.61%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Abbott Laboratories [NYSE: ABT] stock has seen the most recent analyst activity on October 10, 2025, when The Benchmark Company initiated its Buy rating and assigned the stock a price target of $145. Previously, Jefferies upgraded its rating to Buy on July 18, 2025, and kept the price target unchanged to $145. On June 16, 2025, Leerink Partners initiated with a Market Perform rating and assigned a price target of $143 on the stock. Oppenheimer started tracking the stock assigning an Outperform rating and suggested a price target of $130 on October 08, 2024. Piper Sandler initiated its recommendation with an Overweight and recommended $131 as its price target on September 19, 2024. Edward Jones downgraded its rating to Hold for this stock on July 30, 2024. In a note dated May 30, 2024, Goldman initiated a Buy rating and provided a target price of $121 on this stock.
Abbott Laboratories experienced fluctuations in its stock price throughout the past year between $110.86 and $141.23. Currently, Wall Street analysts expect the stock to reach $151.4 within the next 12 months. Abbott Laboratories [NYSE: ABT] shares were valued at $128.47 at the most recent close of the market. An investor can expect a potential return of 17.85% based on the average ABT price forecast.
Analyzing the ABT fundamentals
Trailing Twelve Months sales for Abbott Laboratories [NYSE:ABT] were 43.84B which represents 6.90% growth. Gross Profit Margin for this corporation currently stands at 0.54% with Operating Profit Margin at 0.18%, Pretax Profit Margin comes in at 0.19%, and Net Profit Margin reading is 0.32%. To continue investigating profitability, this company’s Return on Assets is posted at 0.17, Equity is 0.28 and Total Capital is 0.11. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.25.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 125.90 points at the first support level, and at 123.33 for the second support level. However, for the 1st resistance point, the stock is sitting at 130.34, and for the 2nd resistance point, it is at 132.21.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Abbott Laboratories [NYSE:ABT] is 1.70. As well, the Quick Ratio is 1.24, while the Cash Ratio is 0.52. Considering the valuation of this stock, the price to sales ratio is 5.10, the price to book ratio is 4.38 and price to earnings (TTM) ratio is 16.11.
Transactions by insiders
Recent insider trading involved Shroff Eric, Senior Vice President, that happened on Nov 25 ’25 when 1586.0 shares were sold. Officer, Eric Shroff completed a deal on Nov 25 ’25 to buy 1586.0 shares. Meanwhile, EVP AND CFO Boudreau Philip P sold 5550.0 shares on Aug 08 ’25.
